<p>在过去三个月中，4 位分析师分享了他们对 Enovis（纽约证券交易所代码：ENOV）的评估，展现出从看涨到看跌的多样化前景。</p>
<p>总结他们最近的评估，下面的表格展示了过去 30 天情绪的变化，并与前几个月进行了比较。</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看涨</strong></th>
<th align="right"><strong>稍微看涨</strong></th>
<th align="right"><strong>无所谓</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>总评级</strong></td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>过去 30 天</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 个月前</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 个月前</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 个月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>分析师的 12 个月价格目标显示出，平均目标为 44.5 美元，最高估计为 50.00 美元，最低估计为 41.00 美元。当前平均价格目标较之前的 49.50 美元下降了 10.1%。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1767700874_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="价格目标图表" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1767700874_0.png"/></p>
<h2>解读分析师评级：深入分析</h2>
<p>通过对最近分析师行动的全面分析，Enovis 在金融专家中的地位变得清晰。下面的总结概述了关键分析师、他们最近的评估以及对评级和价格目标的调整。</p>
<table>
<thead>
<tr>
<th>分析师</th>
<th>分析师公司</th>
<th>采取的行动</th>
<th>评级</th>
<th>当前价格目标</th>
<th>之前价格目标</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>宣布</td>
<td>买入</td>
<td>41.00 美元</td>
<td>-</td>
</tr>
<tr>
<td>Caitlin Cronin</td>
<td>Canaccord Genuity</td>
<td>下调</td>
<td>买入</td>
<td>50.00 美元</td>
<td>58.00 美元</td>
</tr>
<tr>
<td>Keith Hinton</td>
<td>Freedom Capital Markets</td>
<td>宣布</td>
<td>买入</td>
<td>45.00 美元</td>
<td>-</td>
</tr>
<tr>
<td>Vik Chopra</td>
<td>Wells Fargo</td>
<td>上调</td>
<td>超配</td>
<td>42.00 美元</td>
<td>41.00 美元</td>
</tr>
</tbody>
</table>
<h3>关键见解：</h3>
<ul>
<li><strong>采取的行动：</strong> 针对动态市场条件和公司表现，分析师更新他们的建议。无论是 “维持”、“上调” 还是 “下调” 他们的立场，均表明他们对 Enovis 相关近期发展的反应。这一见解提供了分析师对公司当前状态的快照。</li>
<li><strong>评级：</strong> 分析师从定性角度全面评估股票，评级范围从 “跑赢大盘” 到 “跑输大盘”。这些评级传达了对 Enovis 相对于更广泛市场表现的预期。</li>
<li><strong>价格目标：</strong> 分析师探讨价格目标的动态，为 Enovis 股票的未来价值提供估计。这一审查揭示了分析师预期随时间的变化。</li>
</ul>
<p>通过理解这些分析师评估及相关财务指标，捕捉 Enovis 市场地位的宝贵见解。保持信息灵通，利用我们的评级表做出战略决策。</p>
<p>随时了解 Enovis 分析师评级。</p>
<p>如果您对跟踪小型股新闻和表现感兴趣，您可以从这里开始跟踪。</p>
<h2>探索 Enovis：更深入的了解</h2>
<p>Enovis Corp 是一家医疗技术公司，提供涵盖患者护理全过程的医疗设备和服务，从伤害预防到关节置换，再到手术、伤害或退行性疾病后的康复。其可报告的业务部门包括预防与恢复（P&amp;R）和重建（Recon）。该公司从预防与恢复部门获得最大收入，该部门包括用于治疗因退行性疾病、畸形、创伤事件和运动相关伤害而导致的肌肉骨骼疾病的产品。重建部门提供一系列用于髋关节、膝关节、肩关节、肘关节、足部、踝关节的重建关节产品以及外科生产力工具。从地理上看，其主要收入来自美国。</p>
<h3>解开 Enovis 的财务故事</h3>
<p><strong>市值分析：</strong> 该公司的市值水平较低，处于行业平均水平之下。这表明其相对于同行的规模较小。</p>
<p><strong>收入增长：</strong> Enovis 在 2025 年 9 月 30 日的表现显著，收入增长率达到 <strong>8.65%</strong>。这表明公司顶线收益的显著增加。与同行相比，收入增长落后于行业同行。该公司的增长率低于医疗保健行业同行的平均水平。</p>
<p><strong>净利润率：</strong> Enovis 的净利润率低于行业平均水平，表明在实现强盈利能力方面面临挑战。净利润率为 <strong>-104.05%</strong>，公司可能在有效成本管理方面面临困难。</p>
<p><strong>股本回报率（ROE）：</strong> Enovis 的 ROE 低于行业平均水平，表明在有效利用股本方面可能面临挑战。ROE 为 <strong>-24.84%</strong>，公司可能在实现最佳财务回报方面面临困难。</p>
<p><strong>资产回报率（ROA）：</strong> Enovis 的 ROA 低于行业平均水平，表明在有效利用资产方面可能面临挑战。ROA 为 <strong>-12.08%</strong>，公司可能在从其资产中产生最佳回报方面面临困难。</p>
<p><strong>债务管理：</strong> Enovis 的债务与股本比率为 <strong>0.71</strong>，低于平均水平，表明其采取了谨慎的财务策略，显示出对债务管理的平衡方法。</p>
<h2>分析师评级：它们是什么？</h2>
<p>银行和金融系统的专家，分析师专注于特定股票或定义行业的报告。他们的全面研究包括参加公司电话会议和会议，分析财务报表，并与内部人士互动，以生成所谓的股票分析师评级。通常，分析师每季度评估和评级每只股票一次。</p>
<p>除了标准评估外，一些分析师还提供增长预估、收益和收入等指标的预测，为投资者提供额外的指导。使用分析师评级的用户应注意，这些专业建议受到人类观点的影响，可能会存在变动。</p>
<p>本文由 Benzinga 的自动内容引擎生成，并经过编辑审核。</p>

ENOV

<p>4 位分析师最近对 Enovis (NYSE:ENOV) 进行了评估，显示出看涨和看跌情绪的混合。12 个月的平均目标价为 44.5 美元，较之前的 49.5 美元有所下降，估计范围在 41.00 美元到 50.00 美元之间。分析师们对评级进行了各种调整，有些在市场条件的影响下维持或提高了目标价。Enovis 是一家医疗科技公司，收入增长为 8.65%，但在盈利能力方面面临挑战，净利润率为 -104.05%，股本回报率 (ROE) 为 -24.84%</p>

<p>During the last three months, 4 analysts shared their evaluations of Enovis (NYSE: ENOV), revealing diverse outlooks from bullish to bearish.</p>
<div class="lb-trans"><p>在过去三个月中，4 位分析师分享了他们对 Enovis（纽约证券交易所代码：ENOV）的评估，展现出从看涨到看跌的多样化前景。</p>
</div><p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<div class="lb-trans"><p>总结他们最近的评估，下面的表格展示了过去 30 天情绪的变化，并与前几个月进行了比较。</p>
</div><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看涨</strong></th>
<th align="right"><strong>稍微看涨</strong></th>
<th align="right"><strong>无所谓</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>总评级</strong></td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>过去 30 天</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 个月前</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 个月前</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 个月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
</div><p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $44.5, a high estimate of $50.00, and a low estimate of $41.00. A 10.1% drop is evident in the current average compared to the previous average price target of $49.50.</p>
<div class="lb-trans"><p>分析师的 12 个月价格目标显示出，平均目标为 44.5 美元，最高估计为 50.00 美元，最低估计为 41.00 美元。当前平均价格目标较之前的 49.50 美元下降了 10.1%。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1767700874_0.png" alt="price target chart" original-src="https://www.benzinga.com/files/images/story/2026/1767700874_0.png"/></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<div class="lb-trans"><h2>解读分析师评级：深入分析</h2>
</div><p>The standing of Enovis among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<div class="lb-trans"><p>通过对最近分析师行动的全面分析，Enovis 在金融专家中的地位变得清晰。下面的总结概述了关键分析师、他们最近的评估以及对评级和价格目标的调整。</p>
</div><table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>Announces</td>
<td>Buy</td>
<td>$41.00</td>
<td>-</td>
</tr>
<tr>
<td>Caitlin Cronin</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$50.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Keith Hinton</td>
<td>Freedom Capital Markets</td>
<td>Announces</td>
<td>Buy</td>
<td>$45.00</td>
<td>-</td>
</tr>
<tr>
<td>Vik Chopra</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$42.00</td>
<td>$41.00</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>分析师</th>
<th>分析师公司</th>
<th>采取的行动</th>
<th>评级</th>
<th>当前价格目标</th>
<th>之前价格目标</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>宣布</td>
<td>买入</td>
<td>41.00 美元</td>
<td>-</td>
</tr>
<tr>
<td>Caitlin Cronin</td>
<td>Canaccord Genuity</td>
<td>下调</td>
<td>买入</td>
<td>50.00 美元</td>
<td>58.00 美元</td>
</tr>
<tr>
<td>Keith Hinton</td>
<td>Freedom Capital Markets</td>
<td>宣布</td>
<td>买入</td>
<td>45.00 美元</td>
<td>-</td>
</tr>
<tr>
<td>Vik Chopra</td>
<td>Wells Fargo</td>
<td>上调</td>
<td>超配</td>
<td>42.00 美元</td>
<td>41.00 美元</td>
</tr>
</tbody>
</table>
</div><h3>Key Insights:</h3>
<div class="lb-trans"><h3>关键见解：</h3>
</div><ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Enovis. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Enovis compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Enovis's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>采取的行动：</strong> 针对动态市场条件和公司表现，分析师更新他们的建议。无论是 “维持”、“上调” 还是 “下调” 他们的立场，均表明他们对 Enovis 相关近期发展的反应。这一见解提供了分析师对公司当前状态的快照。</li>
<li><strong>评级：</strong> 分析师从定性角度全面评估股票，评级范围从 “跑赢大盘” 到 “跑输大盘”。这些评级传达了对 Enovis 相对于更广泛市场表现的预期。</li>
<li><strong>价格目标：</strong> 分析师探讨价格目标的动态，为 Enovis 股票的未来价值提供估计。这一审查揭示了分析师预期随时间的变化。</li>
</ul>
</div><p>Capture valuable insights into Enovis's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<div class="lb-trans"><p>通过理解这些分析师评估及相关财务指标，捕捉 Enovis 市场地位的宝贵见解。保持信息灵通，利用我们的评级表做出战略决策。</p>
</div><p>Stay up to date on Enovis analyst ratings.</p>
<div class="lb-trans"><p>随时了解 Enovis 分析师评级。</p>
</div><p>If you are interested in following small-cap stock news and performance you can start by tracking it here.</p>
<div class="lb-trans"><p>如果您对跟踪小型股新闻和表现感兴趣，您可以从这里开始跟踪。</p>
</div><h2>Discovering Enovis: A Closer Look</h2>
<div class="lb-trans"><h2>探索 Enovis：更深入的了解</h2>
</div><p>Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention &amp; Recovery (P&amp;R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention &amp; Recovery segment, which includes products that are used to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports-related injuries. The Reconstructive segment provides a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and surgical productivity tools. Geographically, it derives key revenue from the U.S.</p>
<div class="lb-trans"><p>Enovis Corp 是一家医疗技术公司，提供涵盖患者护理全过程的医疗设备和服务，从伤害预防到关节置换，再到手术、伤害或退行性疾病后的康复。其可报告的业务部门包括预防与恢复（P&amp;R）和重建（Recon）。该公司从预防与恢复部门获得最大收入，该部门包括用于治疗因退行性疾病、畸形、创伤事件和运动相关伤害而导致的肌肉骨骼疾病的产品。重建部门提供一系列用于髋关节、膝关节、肩关节、肘关节、足部、踝关节的重建关节产品以及外科生产力工具。从地理上看，其主要收入来自美国。</p>
</div><h3>Unraveling the Financial Story of Enovis</h3>
<div class="lb-trans"><h3>解开 Enovis 的财务故事</h3>
</div><p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<div class="lb-trans"><p><strong>市值分析：</strong> 该公司的市值水平较低，处于行业平均水平之下。这表明其相对于同行的规模较小。</p>
</div><p><strong>Revenue Growth:</strong> Enovis's remarkable performance in 3M is evident. As of 30 September, 2025, the company achieved an impressive revenue growth rate of <strong>8.65%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<div class="lb-trans"><p><strong>收入增长：</strong> Enovis 在 2025 年 9 月 30 日的表现显著，收入增长率达到 <strong>8.65%</strong>。这表明公司顶线收益的显著增加。与同行相比，收入增长落后于行业同行。该公司的增长率低于医疗保健行业同行的平均水平。</p>
</div><p><strong>Net Margin:</strong> Enovis's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>-104.05%,</strong> the company may face hurdles in effective cost management.</p>
<div class="lb-trans"><p><strong>净利润率：</strong> Enovis 的净利润率低于行业平均水平，表明在实现强盈利能力方面面临挑战。净利润率为 <strong>-104.05%</strong>，公司可能在有效成本管理方面面临困难。</p>
</div><p><strong>Return on Equity (ROE):</strong> Enovis's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-24.84%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<div class="lb-trans"><p><strong>股本回报率（ROE）：</strong> Enovis 的 ROE 低于行业平均水平，表明在有效利用股本方面可能面临挑战。ROE 为 <strong>-24.84%</strong>，公司可能在实现最佳财务回报方面面临困难。</p>
</div><p><strong>Return on Assets (ROA):</strong> Enovis's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-12.08%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<div class="lb-trans"><p><strong>资产回报率（ROA）：</strong> Enovis 的 ROA 低于行业平均水平，表明在有效利用资产方面可能面临挑战。ROA 为 <strong>-12.08%</strong>，公司可能在从其资产中产生最佳回报方面面临困难。</p>
</div><p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.71</strong>, Enovis adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<div class="lb-trans"><p><strong>债务管理：</strong> Enovis 的债务与股本比率为 <strong>0.71</strong>，低于平均水平，表明其采取了谨慎的财务策略，显示出对债务管理的平衡方法。</p>
</div><h2>Analyst Ratings: What Are They?</h2>
<div class="lb-trans"><h2>分析师评级：它们是什么？</h2>
</div><p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<div class="lb-trans"><p>银行和金融系统的专家，分析师专注于特定股票或定义行业的报告。他们的全面研究包括参加公司电话会议和会议，分析财务报表，并与内部人士互动，以生成所谓的股票分析师评级。通常，分析师每季度评估和评级每只股票一次。</p>
</div><p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<div class="lb-trans"><p>除了标准评估外，一些分析师还提供增长预估、收益和收入等指标的预测，为投资者提供额外的指导。使用分析师评级的用户应注意，这些专业建议受到人类观点的影响，可能会存在变动。</p>
</div><p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>
<div class="lb-trans"><p>本文由 Benzinga 的自动内容引擎生成，并经过编辑审核。</p>
</div>

4 位分析师对 Enovis 的评估：你需要了解的内容